Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Gastroenterol Hepatol ; 38(4): 584-589, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2304581

ABSTRACT

BACKGROUND AND AIM: Dedicated studies evaluating the impact of COVID-19 on outcomes of pancreatobiliary IgG4 related disease (IgG4-RD) patients are scarce. Whether COVID-19 infection or vaccination would trigger IgG4-RD exacerbation remains unknown. METHODS: Pancreatobiliary IgG4-RD patients ≥ 18 years old with active follow-up since January 2020 from nine referral centers in Asia, Europe, and North America were included in this multicenter retrospective study. Outcome measures include incidence and severity of COVID-19 infection, IgG4-RD disease activity and treatment status, interruption of indicated IgG4-RD treatment. Prospective data on COVID-19 vaccination status and new COVID-19 infection during the Omicron outbreak were also retrieved in the Hong Kong cohort. RESULTS: Of the 124 pancreatobiliary IgG4-RD patients, 25.0% had active IgG4-RD, 71.0% were on immunosuppressive therapies and 80.6% had ≥ 1 risk factor for severe COVID. In 2020 (pre-vaccination period), two patients (1.6%) had COVID-19 infection (one requiring ICU admission), and 7.2% of patients had interruptions in indicated immunosuppressive treatment for IgG4-RD. Despite a high vaccination rate (85.0%), COVID-19 infection rate has increased to 20.0% during Omicron outbreak in the Hong Kong cohort. A trend towards higher COVID-19 infection rate was noted in the non-fully vaccinated/unvaccinated group (17.6% vs 33.3%, P = 0.376). No IgG4-RD exacerbation following COVID-19 vaccination or infection was observed. CONCLUSION: While a low COVID-19 infection rate with no mortality was observed in pancreatobiliary IgG4-RD patients in the pre-vaccination period of COVID-19, infection rate has increased during the Omicron outbreak despite a high vaccination rate. No IgG4-RD exacerbation after COVID-19 infection or vaccination was observed.


Subject(s)
COVID-19 , Immunoglobulin G4-Related Disease , Humans , Adolescent , Retrospective Studies , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Vaccines , Prospective Studies , Immunoglobulin G , Vaccination , Hong Kong/epidemiology
2.
Curr Treat Options Gastroenterol ; 20(1): 46-59, 2022.
Article in English | MEDLINE | ID: covidwho-1661734

ABSTRACT

Purpose of Review: This paper reviews the latest literature regarding the impact of COVID on endoscopy service provision. Recent Findings: Endoscopy has been shown to be largely safe when appropriate infection prevention and control measures are in place. Endoscopy training and education has been profoundly affected though novel training models to overcome this have been developed. Proper handling of delayed or cancelled procedures is of utmost importance to minimize delays in diagnosis and treatment of diseases such as cancer. Adoption of new technologies such as non-endoscopy alternatives and telehealth may be a viable alternative to minimize infection risks. Summary: This pandemic has led to tangible differences in how we provide endoscopy service in the future. Future research focusing on better risk stratification of patients who need endoscopy, validating novel endoscopy training models, and adopting new technologies are urgently needed to support these changes in the post-pandemic world.

SELECTION OF CITATIONS
SEARCH DETAIL